Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds

Arthritis Care and Research

Volumn 63, Issue SUPPL. 11, 2011, Pages

  Mease, Philip J ^a,b  

^a Rheumatology Associates   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ASSESSMENT TOOL; COMPOSITE PSORIATIC DISEASE ACTIVITY INDEX; DERMATOLOGY LIFE QUALITY INDEX; DISEASE ACTIVITY; DISEASE ACTIVITY IN PSORIATIC ARTHRITIS; DISEASE SEVERITY; ENTHESITIS; ERYTHEMA; FATIGUE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATIGUE; HYPERKERATOSIS; IMAGING; JOINT SWELLING; LEEDS DACTYLITIS INDEX; LEEDS ENTHESITIS INDEX; MAASTRICHT ANKYLOSING SPONDYLITIS ENTHESIS SCORE; MANDER NEWCASTLE ENTHESITIS INDEX; MODIFIED NAIL PSORIASIS SEVERITY INDEX; NAIL; NAIL DYSCHROMIA; NAIL PSORIASIS SEVERITY INDEX; ONYCHOLYSIS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT ASSESSMENT; PATIENT GLOBAL FOR PSORIATIC ARTHRITIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; PSORIATIC ARTHRITIS JOINT ACTIVITY INDEX; PSORIATIC ARTHRITIS QUALITY OF LIFE; PSORIATIC ARTHRITIS RESPONSE CRITERIA; QUALITY OF LIFE; SCORING SYSTEM; SKIN DEFECT; SKIN INDURATION; SPINE; SPONDYLOARTHRITIS RESEARCH CONSORTIUM OF CANADA;

ARTHRITIS, PSORIATIC; CANADA; CHRONIC DISEASE; DERMATOLOGY; ENGLAND; FATIGUE; HUMANS; NAILS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 80855151628     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20577     Document Type: Article

References (125)

1. Mease PJ,. Improving the routine management of rheumatoid arthritis: the value of tight control. J Rheumatol. 2010; 37: 1570-8.
2. Schoels M, Knevel R, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas DT, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis. 2010; 69: 638-43.
3. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
4. Scott DL, Wolfe F, Huizinga TW,. Rheumatoid arthritis. Lancet 2010; 376: 1094-108.
5. Mease PJ,. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis 2011; 70 Suppl: i77-84.
6. Husni ME, Mease PJ,. Managing comorbid disease in patients with psoriatic arthritis. Curr Rheumatol Rep 2010; 12: 281-7.
7. Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007; 34: 1167-70. (Pubitemid 46774868)
8. Mease PJ, Antoni CE,. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005; 64 Suppl: ii78-82. (Pubitemid 40288529)
9. Mease PJ,. Psoriatic arthritis: pharmacotherapy update. Curr Rheumatol Rep 2010; 12: 272-80.
10. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, and the CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73. (Pubitemid 44205029)
11. Van Riel P, Van Gestel A, Scott D,. EULAR handbook of clinical assessment in rheumatoid arthritis. Alpen an den Rijn (The Netherlands): Van Suiden Communications; 2000.
12. Mease P, Antoni C, Gladman DD, Taylor W,. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 Suppl: ii49-54. (Pubitemid 40288522)
13. Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W,. Assessment of patients with psoriatic arthritis: a review of currently available measures [review]. Arthritis Rheum 2004; 50: 24-35. (Pubitemid 38084284)
14. Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006; 65: 1373-8. (Pubitemid 44620449)
15. Englbrecht M, Wang Y, Ronneberger M, Manger B, Vastesaeger N, Veale DJ, et al. Measuring joint involvement in polyarticular psoriatic arthritis: an introduction of alternatives. Arthritis Care Res (Hoboken) 2010; 62: 977-83.
16. Gladman DD, Inman RD, Cook RJ, Maksymowych WP, Braun J, Davis JC, et al. International spondyloarthritis interobserver reliability exercise: the INSPIRE study. II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007; 34: 1740-5. (Pubitemid 47267619)
17. Chandran V, Gottlieb A, Cook RJ, Duffin KC, Garg A, Helliwell P, et al. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Rheum 2009; 61: 1235-42.
18. Buskila D, Langevitz P, Gladman DD, Urowitz S, Smythe HA,. Patients with rheumatoid arthritis are more tender than those with psoriatic arthritis. J Rheumatol 1992; 19: 1115-9.
19. Fredriksson T, Pettersson U,. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44. (Pubitemid 8387357)
20. Long CC, Finlay AY,. The finger-tip unit: a new practical measure. Clin Exp Dermatol 1991; 16: 444-7.
21. Long CC, Finlay AY, Averill RW,. The rule of hand: 4 hand areas = 2 FTU = 1 g. Arch Dermatol 1992; 128: 1129-30.
22. Langley RG, Ellis CN,. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment. J Am Acad Dermatol 2004; 51: 563-9. (Pubitemid 39278075)
23. Krueger GG,. New method being developed for assessing psoriasis. National Psoriasis Foundation Forum 1999; 5: 4-5.
24. Berth-Jones J, Thompson J, Papp K,. A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index. Br J Dermatol 2008; 159: 407-12. (Pubitemid 352009865)
25. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE,. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999; 141: 185-91. (Pubitemid 29397982)
26. Louden BA, Pearce DJ, Lang W, Feldman SR,. A simplified psoriasis area severity index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J 2004; 10: 7.
27. Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Exum ML, Clark AR, et al. The self-administered Psoriasis Area and Severity Index is valid and reliable. J Invest Dermatol 1996; 106: 183-6 (Pubitemid 26052065)
28. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG,. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50: 859-66. (Pubitemid 38691110)
29. Rich P, Scher RK,. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206-12. (Pubitemid 36951265)
30. Aktan S, Ilknur T, Akin C, Ozkan S,. Interobserver reliability of the Nail Psoriasis Severity Index. Clin Exp Dermatol 2007; 32: 141-4. (Pubitemid 46233014)
31. Cassell SE, Bieber JD, Rich P, Tutuncu ZN, Lee SJ, Kalunian KC, et al. The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007; 34: 123-9. (Pubitemid 46106572)
32. Augustin M, Ogilvie A,. Methods of outcomes measurement in nail psoriasis. Dermatology 2010; 221 Suppl: 23-8.
33. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60: 976-86.
34. McGonagle D, Lories RJ, Tan AL, Benjamin M,. The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007; 56: 2482-91. (Pubitemid 47237267)
35. Gladman DD, Chandran V,. Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. Rheumatology (Oxford) 2011; 50: 25-31.
36. Mander M, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick WC,. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987; 46: 197-202. (Pubitemid 17035449)
37. Healy PJ, Helliwell PS,. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008; 59: 686-91. (Pubitemid 351679544)
38. Maksymowych WP, Mallon C, Morrow S, Shojania K, Olszynski WP, Wong RL, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 2009; 68: 948-53.
39. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewe R, van ver Tempel H, Mielants H, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62: 127-32. (Pubitemid 36135387)
40. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-93. (Pubitemid 34304258)
41. Gorman JD, Sack KE, Davis JC Jr,. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002; 346: 1349-56. (Pubitemid 34754607)
42. Coates LC, Helliwell PS,. Disease measurement: enthesitis, skin, nails, spine and dactylitis. Best Pract Res Clin Rheumatol 2010; 24: 659-70.
43. Helliwell PS, Firth J, Ibrahim GH, Melsom RD, Shah I, Turner DE,. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 2005; 32: 1745-50. (Pubitemid 41324815)
44. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis 2011; 70 Suppl: i2-36.
45. Healy PJ, Helliwell PS,. Measuring dactylitis in clinical trials: which is the best instrument to use? J Rheumatol 2007; 34: 1302-6. (Pubitemid 46898112)
46. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A,. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
47. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-5.
48. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A,. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994; 21: 1694-8. (Pubitemid 24285485)
49. Taylor WJ, Harrison AA,. Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum 2004; 51: 311-5. (Pubitemid 38725126)
50. Leung YY, Tam LS, Kun EW, Ho KW, Li EK,. Comparison of 4 functional indexes in psoriatic arthritis with axial or peripheral disease subgroups using Rasch analyses. J Rheumatol 2008; 35: 1613-21.
51. Gladman D, Inman R, Cook RJ, van der Heijde D, Landewe RB, Braun J, et al. International spondyloarthritis interobserver reliability exercise: the INSPIRE study. I. Assessment of spinal measures. J Rheumatol 2007; 34: 1733-9. (Pubitemid 47267618)
52. Fernandez-Sueiro JL, Willisch A, Pertega-Diaz S, Tasende JA, Fernandez-Lopez C, Galdo F, et al. Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis. Arthritis Rheum 2009; 61: 386-92.
53. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 18-24.
54. Eder L, Chandran V, Shen H, Cook RJ, Gladman DD,. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis 2010; 69: 2160-4.
55. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40. (Pubitemid 23175613)
56. Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 2011; 38: 898-903.
57. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9: 105-21. (Pubitemid 351147828)
58. Fries JF, Spitz P, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45. (Pubitemid 10164318)
59. Blackmore MG, Gladman DD, Husted J, Long JA, Farewell VT,. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol 1995; 22: 886-93.
60. Husted JA, Gladman DD, Long JA, Farewell VT,. A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Clin Exp Dermatol 1995; 13: 439-43.
61. Husted JA, Tom BD, Farewell VT, Schentag CT, Gladman DD,. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time? Arthritis Rheum 2007; 56: 840-9. (Pubitemid 46399432)
62. Taylor WJ, McPherson KM,. Using Rasch analysis to compare the psychometric properties of the Short Form 36 physical function score and the Health Assessment Questionnaire disability index in patients with psoriatic arthritis and rheumatoid arthritis. Arthritis Rheum 2007; 57: 723-9. (Pubitemid 46932076)
63. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ,. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90. (Pubitemid 30487495)
64. Mease PJ, Woolley JM, Bitman B, Wang B, Globe D, Singh A,. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol. E-pub ahead of print.
65. Mease P, Ganguly L, Wanke E, Yu E, Singh A,. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) group guidelines [abstract]. Ann Rheum Dis 2004; 63 Suppl: 391.
66. Kwok T, Pope JE,. Minimally important difference for patient-reported outcomes in psoriatic arthritis: Health Assessment Questionnaire and pain, fatigue, and global visual analog scales. J Rheumatol 2010; 37: 1024-8.
67. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr,. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43: 1478-87. (Pubitemid 30452465)
68. Husted J, Gladman DD, Long JA, Farewell VT,. Relationship of the Arthritis Impact Measurement Scales to changes in articular status and functional performance in patients with psoriatic arthritis. J Rheumatol 1996; 23: 1932-7. (Pubitemid 26376119)
69. Husted J, Gladman DD, Farewell VT, Long JA,. Validation of the revised and expanded version of the Arthritis Impact Measurement Scales for patients with psoriatic arthritis. J Rheumatol 1996; 23: 1015-9. (Pubitemid 26196091)
70. Ware JE Jr, Sherbourne CD,. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
71. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-6. (Pubitemid 24194579)
72. The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
73. Husted JA, Gladman DD, Farewell VT, Long JA, Cook RJ,. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997; 24: 511-7. (Pubitemid 27153417)
74. Nichol MB, Margolies JE, Lippa E, Rowe M, Quell J,. The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis. Pharmacoeconomics 1996; 10: 644-53. (Pubitemid 26401710)
75. Kurwa HA, Finlay AY,. Dermatology in-patient management greatly improves life quality. Br J Dermatol 1995; 133: 575-8.
76. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-94.
77. McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ,. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004; 63: 162-9. (Pubitemid 38122135)
78. Healy PJ, Helliwell PS,. Psoriatic arthritis quality of life instrument: an assessment of sensitivity and response to change. J Rheumatol 2008; 35: 1359-61. (Pubitemid 352000784)
79. Stamm TA, Nell V, Mathis M, Coenen M, Aletaha D, Cieza A, et al. Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning. Arthritis Rheum 2007; 57: 487-94. (Pubitemid 46682538)
80. Kirwan JR, Newman S, Tugwell PS, Wells GA,. Patient perspective on outcomes in rheumatology: a position paper for OMERACT 9. J Rheumatol 2009; 36: 2067-70.
81. Minnock P, Kirwan J, Veale D, Fitzgerald O, Bresnihan B,. Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis. Clin Exp Rheumatol 2010; 28: 401-4.
82. Belza BL, Henke CJ, Yelin EH, Epstein WV, Gilliss CL,. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 1993; 42: 93-9.
83. Smets EM, Garssen B, Bonke B, De Haes JC,. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995; 39: 315-25.
84. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD,. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-3. (Pubitemid 19246303)
85. Cella D, Lai JS, Chang CH, Peterman A, Slavin M,. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002; 94: 528-38. (Pubitemid 34081385)
86. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et al. The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer 1999; 85: 1186-96. (Pubitemid 29115600)
87. Wolfe F, Hawley DJ, Wilson K,. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996; 23: 1407-17. (Pubitemid 26258765)
88. Schentag CT, Cichon J, MacKinnon A, Gladman DD, Urowitz MB,. Validation and normative data for the 0-10 point scale version of the fatigue severity scale (FSS) [abstract]. Arthritis Rheum 2000; 43 Suppl: S177.
89. Schentag C, Gladman D,. Changes in fatigue in psoriatic arthritis: disease activity of fibromyalgia [abstract]. Arthritis Rheum 2002; 46 Suppl: S424.
90. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al, for the Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279-89. (Pubitemid 41447111)
91. Chandran V, Bhella S, Schentag C, Gladman DD,. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis 2007; 66: 936-9. (Pubitemid 46999797)
92. Cella D,. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system. Evanston (IL): Center on Outcomes, Research, and Education, Evanston Northwestern Healthcare and Northwestern University; 1997.
93. Webster K, Cella D, Yost K,. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 2003; 1: 79.
94. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E,. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13: 63-74. (Pubitemid 27147321)
95. Reeve BB, Hays RD, Bjorner JB, Cook KF, Crane PK, Teresi JA, et al. Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care 2007; 45 Suppl: S22-31.
96. Mease P, van der Heijde D,. Joint damage in psoriatic arthritis: how is it assessed and can it be prevented? Int J Adv Rheumatol 2006; 4: 38-48.
97. Van der Heijde D, Sharp J, Wassenberg S, Gladman DD,. Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 2005; 64 Suppl: ii61-4. (Pubitemid 40288525)
98. Lubrano E, Marchesoni A, Olivieri I, D'Angelo S, Spadaro A, Parsons WJ, et al. The radiological assessment of axial involvement in psoriatic arthritis: a validation study of the BASRI total and the modified SASSS scoring methods. Clin Exp Rheumatol 2009; 27: 977-80.
99. Lubrano E, Marchesoni A, Olivieri I, D'Angelo S, Spadaro A, Parsons WJ, et al. Psoriatic Arthritis Spondylitis Radiology Index: a modified index for radiologic assessment of axial involvement in psoriatic arthritis. J Rheumatol 2009; 36: 1006-11.
100. Sturrock RD,. Clinical utility of ultrasonography in spondyloarthropathies. Curr Rheumatol Rep 2009; 11: 317-20.
101. Kane D,. The role of ultrasound in the diagnosis and management of psoriatic arthritis. Curr Rheumatol Rep 2005; 7: 319-24.
102. Dougados M, Jousse-Joulin S, Mistretta F, d'Agostino MA, Backhaus M, Bentin J, et al. Evaluation of several ultrasonography scoring systems for synovitis and comparison to clinical examination: results from a prospective multicentre study of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 828-33.
103. Balint PV, Kane D, Wilson H, McInnes IB, Sturrock RD,. Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy. Ann Rheum Dis 2002; 61: 905-10.
104. Gisondi P, Tinazzi I, El-Dalati G, Gallo M, Biasi D, Barbara LM, et al. Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. Ann Rheum Dis 2008; 67: 26-30.
105. Ostergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B, et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies: core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system [published erratum appears in J Rheumatol 2004;31:198]. J Rheumatol 2003; 30: 1385-6. (Pubitemid 36666373)
106. McQueen F, Lassere M, Bird P, Haavardsholm EA, Peterfy C, Conaghan PG, et al. Developing a magnetic resonance imaging scoring system for peripheral psoriatic arthritis. J Rheumatol 2007; 34: 859-61. (Pubitemid 46641399)
107. Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011; 63: 939-48.
108. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996; 39: 2013-20.
109. Gladman DD, Tom BD, Mease PJ, Farewell VT,. Informing response criteria for psoriatic arthritis. I. Discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. J Rheumatol 2010; 37: 1892-7.
110. Gladman DD, Tom BD, Mease PJ, Farewell VT,. Informing response criteria for psoriatic arthritis (PsA). II. Further considerations and a proposal: the PsA joint activity index. J Rheumatol 2010; 37: 2559-65.
111. Gladman DD, Psaradellis F, Illouz O, Sampalis JS,. Evaluation of response using the psoriatic arthritis joint activity index scoring tool in patients treated with adalimumab: post hoc analysis of the ACCLAIM study [abstract]. J Rheumatol 2009; 38: 2571.
112. Nell-Duxneuner VP, Stamm TA, Machold KP, Pflugbeil S, Aletaha D, Smolen JS,. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis 2010; 69: 546-9.
113. Eberl G, Studnicka-Benke A, Hitzelhammer H, Gschnait F, Smolen JS,. Development of a disease activity index for the assessment of reactive arthritis (DAREA). Rheumatology (Oxford) 2000; 39: 148-55. (Pubitemid 30139347)
114. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS,. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010; 69: 1441-7.
115. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 1150-7. (Pubitemid 41113349)
116. Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale JD, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2010; 70: 272-7.
117. Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale JD, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2010; 70: 272-7.
118. FitzGerald O, Helliwell P, Mumtaz A, Coates L, Pedersen R, Molta C,. Application of composite disease activity scores in psoriatic arthritis to the PRESTA dataset [abstract]. Arthritis Rheum 2010; 62 Suppl: S214.
119. Saber TP, Ng CT, Renard G, Lynch BM, Pontifex E, Walsh CA, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther 2010; 12: R94.
120. Pinals RS, Masi AT, Larsen RA, and the Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-15. (Pubitemid 11022943)
121. Cantini F, Niccoli L, Nannini C, Cassara E, Pasquetti P, Olivieri I, et al. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology (Oxford) 2008; 47: 872-6. (Pubitemid 351796376)
122. Coates LC, Fransen J, Helliwell PS,. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010; 69: 48-53.
123. Coates LC, Cook R, Lee KA, Chandran V, Gladman DD,. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken) 2010; 62: 970-6.
124. Coates LC, Helliwell PS,. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 2010; 62: 965-9.
125. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003; 62: 20-6. (Pubitemid 36005790)